Skip to main content

Table 2 Studies addressing the risk related to previous antibiotic therapy and emergence of carbapenem-resistant Enterobacteriaceae

From: Piperacillin–tazobactam as alternative to carbapenems for ICU patients

  Year Study design Type of infection Antibiotic concerned OR, 95 % CI
Wang [62] 2016 Retrospective case–case–control Nosocomial infection Third–fourth-generation cephalosporins
Carbapenems
4.557 (1.971–10.539)
4.058 (1.753–9.397)
Mittal G [80] 2016 Prospective Colonization Aminoglycosides 4.14 (1.14–14.99)
Ling [81] 2015 Retrospective case–control Infection or colonization Penicillins
Glycopeptides
4.640 (1.529–14.079)
5.162 (1.377–19.346)
Jiao Y [82] 2015 Retrospective case–control Infection or colonization Glycopeptides
Cefoperazone plus sulbactam
43.84 (1.73–1111.9)
49.56, (1.42–1726.72)
Candevir [83] 2015 Retrospective cohort Infection Meropenem
Third-generation cephalosporins
3.244 (1.193–8.819)
3.590 (1.056–12.209)
Gómez Rueda [84] 2014 Retrospective case–case–control Infection Carbapenems 3.3 (1.2–9.3)
Ahn [85] 2014 Retrospective case–control Colonization/infection Fluoroquinolones
Carbapenems
2.82 (1.14–6.99)
4.56 (1.44–14.46)
Mantzarlis [86] 2013 Prospective cohort Pneumonia Colistin* 1.156 per day (1.010–1.312)
Dizbay [87] 2013 Prospective cohort Nosocomial infection Imipenem 3.35 (1.675–6.726)
Orsi [88] 2013 Retrospective case control BSI Carbapenem 7.74 (1.70–35.2)
Chang [89] 2011 Retrospective case–control BSI Carbapenem 29.17 (1.76–484.70)
Falagas [63] 2007 Retrospective case control KPC infection Fluoroquinolones
Antipseudomonal antibiotics
4.54 (1.18–11.54)
2.6 (1.00–6.71)
Schwaber [61] 2008 Retrospective case–case–control CRKp colonization Antibiotics
Fluoroquinolones
4.4 (1–19.2)
7.2 (1.1–49.4)
Gasink [60] 2009 Retrospective case–control KPC infection/colonization Fluoroquinolones
Third-generation cephalosporin
3.39 (1.5–7.66)
2.55 (1.18–5.22)
Papadimitriou [64] 2012 Prospective cohort CRKp colonization BL/BLI
Carbapenems
6.7 (1–26.2)
5.2 (1–32.9)
Tuon [90] 2012 Retrospective case–control KPC bacteremia Fluoroquinolones 28.9 (1.85–454.6)
Papadimitriou [91] 2014 Prospective cohort KPC bacteremia Aminoglycosides 2.3 (1.1–4.7)
Gagliotti [79] 2014 Case–control KPC colonization Carbapenems
Any antibiotic (other than carbapenems)
3.67 (1.37–9.83)
2.83 (1.10–7.31)
Maseda [92] 2016 Retrospective CPE isolate colonization Third–fourth-generation cephalosporins
BL/BLI
27.96 (6.88–113.58)
11.71 (4.51–30.43)
  1. KPC Klebsiella pneumoniae-producing carbapenemase, CRKp carbapenem-resistant Klebsiella pneumoniae, BL/BLI beta-lactams associated with beta-lactamase inhibitors, BSI bloodstream infection